Depression Clinical Trials in Atlanta, GA

43 recruiting studies within 50 miles

Phase

Trial	Phase	Sponsor	Dist.
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.	Phase 3	AbbVie	<1 mi
A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder	Phase 2	AbbVie	<1 mi
Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)	N/A	Abbott Medical Devices	<1 mi
Inflammation and Depression in People With HIV	Phase 2	Emory University	<1 mi
Suicidal Behavior in Patients Diagnosed With Bipolar Disorder	N/A	Emory University	<1 mi
Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.	Phase 2	LB Pharmaceuticals Inc.	<1 mi
The OBSERVE Protocol	—	Yale University	<1 mi
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder	Phase 3	Intra-Cellular Therapies, Inc.	<1 mi
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)	Phase 3	Neurocrine Biosciences	<1 mi
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder	Phase 3	Janssen Research & Development, LLC	<1 mi
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients	Phase 3	Intra-Cellular Therapies, Inc.	<1 mi
ALTO-100 in Bipolar Disorder With Depression (BD-D)	Phase 2	Alto Neuroscience	<1 mi
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)	Phase 3	Definium Therapeutics US, Inc.	<1 mi
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)	Phase 3	Xenon Pharmaceuticals Inc.	<1 mi
Dopaminergic Therapy for Anhedonia - 2	Phase 4	Emory University	<1 mi
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms	Phase 3	Janssen Research & Development, LLC	<1 mi
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression	N/A	LivaNova	<1 mi
JAK Signaling in Depression	Phase 2	Emory University	<1 mi
PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study	Phase 3	Yale University	<1 mi
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms	Phase 4	Axsome Therapeutics, Inc.	<1 mi
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)	Phase 3	Neurocrine Biosciences	<1 mi
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder	Phase 3	Xenon Pharmaceuticals Inc.	<1 mi
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder	Phase 3	Cybin IRL Limited	<1 mi
Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)	Phase 2	Autobahn Therapeutics, Inc.	<1 mi
ALTO-207 in Adults With Treatment-resistant Depression (TRD)	Phase 2	Alto Neuroscience	<1 mi
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder	Phase 2	AbbVie	<1 mi
Leucine in Midlife Depression	Phase 2	Emory University	<1 mi
Mechanisms of Behavioral Activation (BA)	N/A	Emory University	<1 mi
Brain Stimulation and Decision-making	N/A	Emory University	<1 mi
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)	Phase 3	Xenon Pharmaceuticals Inc.	<1 mi
Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine	Early 1	Emory University	<1 mi
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression	Phase 2	Draig Therapeutics Ltd	<1 mi
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"	Phase 3	Cybin IRL Limited	<1 mi
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)	Phase 2	Seaport Therapeutics	<1 mi
E-Mindfulness Approaches for Living After Breast Cancer	Phase 3	NRG Oncology	<1 mi
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses	Phase 2	Reunion Neuroscience Inc	<1 mi
A Study of Brenipatide in Adult Participants With Major Depressive Disorder	Phase 3	Eli Lilly and Company	6 mi
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)	Phase 2	atai Therapeutics, Inc.	6 mi
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder	Phase 2	Syndeio Biosciences, Inc	13 mi
A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)	Phase 2	Tonix Pharmaceuticals, Inc.	17 mi
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor	Phase 4	Neurocrine Biosciences	17 mi
Study of ALTO-300 in MDD	Phase 2	Alto Neuroscience	22 mi
A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder	Phase 3	Janssen Research & Development, LLC	22 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.